Home How It Works Goals Protocols Lab Tests Peptides Blog About Log In Get Started

GH Secretagogue — GHRH Analog (1-29)

Sermorelin — Growth Hormone-Releasing Hormone Analog

Sermorelin is the synthetic 29-amino acid analog of endogenous GHRH and the original GHRH-class compound with the longest clinical safety record — built from its prior FDA approval as Geref for pediatric growth hormone deficiency. Compounded sermorelin for adult GH support remains one of the most widely used GHS options in clinical telehealth. Evidence level: Level III–IV (pediatric GHD approval history + limited adult observational data).

Start a Consultation Back to GH Secretagogues

What sermorelin is

The original GHRH analog — with a clinical history that distinguishes it from newer compounds.

Sermorelin occupies a unique position among GH secretagogues: it is the closest structural analog to endogenous GHRH, has the longest documented clinical use history, and carries a compounding track record built on its former FDA approval status. Understanding its molecular characteristics and clinical context explains both its appeal and its limitations compared to newer analogs.

Molecular Structure — GHRH (1-29)

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of endogenous human growth hormone-releasing hormone (GHRH 1-29). Endogenous GHRH is a 44-amino acid hypothalamic peptide; research established that the biological activity of the full-length molecule resides primarily within the first 29 residues. Sermorelin replicates this biologically active fragment with minimal modification — making it the most structurally conservative GHRH analog available. Its molecular formula is C₁₄₉H₂₄₆N₄₄O₄₂S and it has a molecular weight of approximately 3,357.9 Da.

Prior FDA Approval — Geref (Serono)

Sermorelin was previously FDA-approved under the brand name Geref (sermorelin acetate, manufactured by Serono Laboratories) for use in both diagnostic testing of GH secretory capacity and for treatment of growth failure in children with inadequate endogenous GH secretion. This approval provided a substantial body of clinical safety and efficacy data — particularly in pediatric populations — that distinguishes sermorelin from compounds with no prior clinical development pathway. Serono voluntarily discontinued Geref for commercial reasons; the withdrawal was not a safety action by the FDA.

Mechanism — GHRH Receptor Agonism

Sermorelin binds to and activates GHRH receptors (GHRH-R) on somatotroph cells in the anterior pituitary gland. Receptor binding triggers a G-protein coupled cascade — activating adenylyl cyclase, increasing intracellular cAMP, and activating protein kinase A (PKA) — which ultimately stimulates GH synthesis and secretion. The GH released travels to the liver and other target tissues, stimulating IGF-1 production. Sermorelin's mechanism is identical in target and signaling pathway to endogenous GHRH; its pharmacological distinction is improved enzymatic stability relative to the native peptide.

Half-Life and Pharmacokinetics

Sermorelin has a plasma half-life of approximately 10–12 minutes after subcutaneous injection — shorter than CJC-1295 without DAC (~30 min) and far shorter than CJC-1295 with DAC (~6–8 days). This short half-life means sermorelin must be dosed precisely timed to the desired GH pulse — most commonly at bedtime to align with the largest endogenous nocturnal GH pulse. It is cleared by serum proteases and renal excretion. The short half-life is both a limitation (narrow dosing window) and a feature (rapid clearance minimizes sustained off-target GH exposure).

Comparison to CJC-1295 and Tesamorelin

Among GHRH analogs, sermorelin is the most structurally native (closest to endogenous GHRH), CJC-1295 is an engineered second-generation analog with improved stability, and tesamorelin is a stabilized analog with the strongest human clinical trial evidence base and FDA approval for a body composition indication. Sermorelin's clinical advantage is its safety track record — it is generally considered the most conservatively positioned option, with the longest history of clinical use and the most established tolerability data. Newer analogs may offer greater duration of action or efficacy, but with less clinical history.

Compounding History and Adult Use

Following Serono's voluntary withdrawal of Geref, compounding pharmacies began preparing sermorelin acetate for adult clinical use based on its prior approval history and established safety profile. Sermorelin appears on various state pharmacy board-approved compound lists and has been used in adult GH optimization and anti-aging medicine contexts for over a decade. Its compounding use predates many of the newer GHRH analogs and accounts for its widespread familiarity among clinicians in this therapeutic space. Off-label use in non-pediatric populations is not FDA-approved — all adult use is off-label compounding.

How it may work

Pulsatile GH stimulation — preserving the body's own regulatory architecture.

Sermorelin's clinical rationale rests on its ability to support the body's natural GH secretory machinery — the hypothalamic-pituitary axis — rather than bypassing it with exogenous hormone.

Stimulating Endogenous GH Release

Sermorelin acts on the pituitary's somatotroph cells, triggering the release of the body's own GH. This is distinct from exogenous recombinant human GH (rhGH), which delivers synthetic hormone directly into circulation and suppresses natural pituitary GH production via negative feedback. By working through the pituitary, sermorelin preserves the regulatory architecture of the GH/IGF-1 axis.

Nocturnal GH Pulse Alignment

In healthy adults, the dominant GH pulse occurs during slow-wave sleep (stage 3 NREM), typically 60–90 minutes after sleep onset. Bedtime sermorelin administration positions GHRH receptor stimulation to augment this natural pulse. Clinical protocols almost universally specify bedtime dosing for this reason — the timing maximizes physiologic relevance of the induced GH release and may support sleep quality as a downstream effect.

IGF-1 Axis Stimulation

GH secreted following sermorelin administration stimulates hepatic IGF-1 production. IGF-1 mediates many of GH's anabolic and lipolytic effects — lean tissue maintenance, visceral fat reduction, collagen and connective tissue synthesis, and bone mineral density support. IGF-1 also feeds back to the hypothalamus and pituitary, signaling somatostatin release that dampens further GH release. This negative feedback loop is intact with sermorelin — a key safety distinction from exogenous GH administration.

Age-Related GH Support

GH secretion declines with age (somatopause), with total daily GH output falling progressively after the third decade. In adults over 40, IGF-1 levels are frequently below the normal range for younger adults. Sermorelin may support age-appropriate GH/IGF-1 axis activity by augmenting pituitary responsiveness — evidence suggests suggests the pituitary retains meaningful capacity to respond to GHRH stimulation even in older adults, provided the somatotroph cells remain functional.

Body Composition — What Evidence Suggests

Elevated GH and IGF-1 may support: improved lean muscle mass relative to fat mass, reduced visceral adiposity, enhanced post-exercise recovery, and improved connective tissue integrity. These effects are established in GH deficiency treatment literature and extrapolated to GHS protocols. For sermorelin specifically, adult clinical data are primarily observational — meaningful patient-reported and clinician-assessed outcomes, but not the randomized controlled trial level evidence available for tesamorelin. Evidence suggests benefit; controlled confirmation is limited.

Pituitary Preservation vs. Exogenous GH

A clinically significant feature of all GHRH analogs is that they do not suppress the pituitary's endogenous GH production — unlike exogenous rhGH, which chronically downregulates somatotroph function. Clinicians often view sermorelin and other GHRH analogs as "pituitary-friendly" in this respect: the pituitary gland continues to exercise its secretory function, and endogenous GH/IGF-1 regulation remains physiologically engaged throughout treatment. This theoretical advantage has not been confirmed in long-term comparative human trials.

Clinical evidence

The research basis for sermorelin — pediatric approval history and adult observational data.

Sermorelin's evidence base is grounded in its former FDA-approved use in pediatric GHD and a limited body of adult studies. The pediatric clinical history provides meaningful safety context that newer GHRH analogs lack, but adult efficacy RCT evidence remains limited.

Pediatric GHD Clinical Program — Former FDA Approval

Geref NDA — Serono Laboratories · Evidence: Level II (clinical approval basis)

Sermorelin's FDA approval as Geref was based on controlled clinical studies in children with growth hormone deficiency demonstrating both diagnostic utility (GH stimulation testing) and treatment efficacy (increased growth velocity). The pediatric clinical program established sermorelin's safety profile in a sensitive population — children — over multi-year protocols. While adult use is a distinct clinical context, this approval history provides a meaningful foundation for understanding sermorelin's tolerability and pharmacological behavior that is absent for never-approved GHS compounds.

GHS in Adults — Systematic Review

DOI: 10.21037/tau.2019.11.30 · Sinha et al. 2020 · Evidence: Level III (systematic review)

This systematic review of GH secretagogues in men with hypogonadism or metabolic syndrome included sermorelin among the compounds reviewed. The review identified sermorelin as a potent GH/IGF-1 stimulator with body composition signals in limited adult data. The authors' conclusion — that "a paucity of data examining clinical effects currently limits our understanding" and that high-quality long-term RCTs are needed — accurately characterizes the adult evidence landscape for sermorelin. The review supports sermorelin's pharmacological activity without confirming body composition efficacy in controlled adult trials.

Tesamorelin Phase 3 — GHRH Analog Class Context

PMID: 20554713 · Falutz et al., J Clin Endocrinol Metab 2010 · Evidence: Level I (Phase 3 RCT)

While tesamorelin's Phase 3 RCT data are specific to a different GHRH analog and a distinct patient population (HIV-associated lipodystrophy), they provide the strongest available human evidence that GHRH-class stimulation of the GH/IGF-1 axis can produce meaningful body composition changes — a −24 cm² reduction in visceral adipose tissue versus placebo. This class-level evidence supports the mechanistic rationale for sermorelin use, while the specific body composition evidence for sermorelin in healthy aging adults remains at the observational level.

Evidence Level Framing

Overall evidence grade: Level III–IV (adult use)

Sermorelin's clinical evidence hierarchy for adult GH support is: Level I safety history (from pediatric GHD approval); Level III adult efficacy (systematic review of limited studies); and Level IV direct adult body composition data (observational, clinician-reported). For context, this is stronger than compounds with no prior clinical development history but weaker than tesamorelin's Phase 3 RCT evidence base. The gap between sermorelin's established safety profile and its limited adult efficacy RCT evidence is a known limitation that should be discussed explicitly with your clinician.

Dosing context — educational only

Clinical dosing patterns — with important caveats.

⚠ EDUCATIONAL ONLY — Not a Prescription. No FDA-Approved Adult Protocol.

Sermorelin is not FDA-approved for adult use in any indication. All dosing described below refers to off-label compounding use in clinical telehealth settings and is provided for informational purposes only. Dosing must be individualized by a qualified prescribing clinician based on patient history, baseline IGF-1 levels, goals, and ongoing monitoring. Self-administration without clinical supervision is not appropriate.

Subcutaneous Injection — Bedtime Timing

Sermorelin is administered subcutaneously — typically in the abdomen or lateral thigh — and the standard clinical approach is bedtime dosing. Typical dose ranges described in clinical telehealth settings are 100–500 mcg per injection, administered once nightly. The range reflects individual response variation and is guided by baseline IGF-1 levels and clinical response monitoring. Lower doses (100–200 mcg) are commonly used as starting points, with upward titration based on IGF-1 response.

Cycle Duration and Treatment Breaks

Clinical programs typically use 3–6 month treatment cycles, followed by a 4–8 week break. Treatment breaks help prevent receptor desensitization from continuous GHRH receptor stimulation. IGF-1 monitoring at baseline, mid-cycle, and end-of-cycle guides decisions about dose adjustment, cycle continuation, and treatment breaks. The need for cycling is based on clinical experience with GHRH analogs and is not formally validated in published RCTs specifically for sermorelin in adults.

Combination with Ipamorelin

Sermorelin is sometimes combined with ipamorelin in clinical practice, similar to the CJC-1295/Ipamorelin combination, to achieve synergistic dual-pathway GH stimulation. In a combination protocol, sermorelin and ipamorelin are typically co-administered in the same injection at bedtime. The clinician's assessment of individual patient goals, tolerance, and baseline status determines whether monotherapy sermorelin or a combination approach is appropriate.

Safety considerations

A well-characterized safety profile — with important clinical considerations.

Sermorelin's pediatric GHD approval history provides a more robust safety data set than most GHS compounds. Adult use carries a favorable tolerability profile based on clinical experience, with the following considerations requiring clinician evaluation.

Injection Site Reactions

Subcutaneous injection site reactions — including redness, swelling, itching, and discomfort — have been reported in both the pediatric approval studies and adult clinical use. These are typically mild and self-limited. Rotating injection sites and proper subcutaneous technique minimize these reactions. Persistent or worsening site reactions should be reported to the prescribing clinician.

GH-Mediated Side Effects

Water retention, mild peripheral edema, joint discomfort, and transient tingling or numbness in the extremities are GH-class effects observed with sermorelin use. These effects are dose-dependent and typically resolve with dose adjustment or treatment discontinuation. They are most common during the initial weeks of therapy when GH and IGF-1 levels are rising. Dose titration should proceed gradually to minimize these effects.

Headache

Headache has been reported in sermorelin clinical use, particularly in early treatment. The mechanism is not fully characterized but may be related to GH-mediated intracranial pressure changes or vascular effects. Transient headache is generally not dose-limiting, but persistent or severe headache should be evaluated clinically. This was documented in the Geref approval-era safety data.

Glucose Monitoring

Elevated GH exerts anti-insulin activity — it reduces peripheral glucose uptake and stimulates hepatic gluconeogenesis. In healthy adults with normal glucose metabolism, standard sermorelin doses do not typically produce clinically significant glucose dysregulation. In patients with pre-diabetes, insulin resistance, or type 2 diabetes, fasting glucose and HbA1c monitoring is appropriate throughout treatment. This is a class consideration for all GHRH analogs.

Active Malignancy — Evaluation Required

GH and IGF-1 have mitogenic activity and are potential growth factors for some tumor types. Any GHS protocol requires explicit clinician evaluation of personal and family cancer history — particularly hormone-sensitive cancers — before initiation. Active malignancy is a contraindication to GH-elevating therapies. The theoretical oncogenic concern is the primary long-term safety consideration for all GH secretagogue compounds.

Contraindications — Pituitary Pathology

Sermorelin is contraindicated in patients with pituitary tumors, pituitary hyperplasia, or other conditions in which GH excess would be clinically harmful. Prior pituitary surgery or head irradiation affecting the hypothalamic-pituitary axis should be disclosed to and evaluated by the prescribing clinician. Pregnancy and nursing: contraindicated. Pediatric patients below approved age thresholds for GHD treatment: off-label status requires exceptional clinical justification.

Regulatory status — 2026

Prior FDA approval, voluntary withdrawal, and compounding status.

Former FDA Approval, Voluntary Withdrawal, and Current Compounding Context

Sermorelin was previously FDA-approved as Geref (sermorelin acetate, Serono Laboratories) for pediatric growth hormone deficiency diagnosis and treatment. The approval was voluntarily withdrawn by Serono for commercial reasons — not due to FDA safety action or efficacy concerns. This voluntary withdrawal is a critical distinction: sermorelin is not prohibited or restricted by the FDA; the branded product simply no longer exists on the market.

Compounded sermorelin for adult use has been prepared by 503A compounding pharmacies based on its prior approval history and established safety profile. Sermorelin appears on various state pharmacy board-approved compound lists. However, as of mid-2026, sermorelin is not on the federal FDA-approved 503A bulk drug substances list. Compounding availability and legality should be confirmed with a licensed compounding pharmacy and compliance counsel at the time of consultation, as regulatory guidance evolves. Sermorelin is addressed via 503A compounding when clinically appropriate and when compounding status is compliant with current requirements.

Not FDA-Approved for Adult GH Support

Sermorelin has no current FDA approval for any indication. Its former approval was pediatric-specific and is no longer in effect. Adult use for GH secretion support is off-label in all cases. No NDA for adult sermorelin use has been filed or approved. The prior approval provides meaningful safety and efficacy context but does not constitute current approval for any adult indication.

WADA Status — Prohibited in Competitive Sports

Sermorelin is prohibited in sanctioned competitive sports under the WADA Prohibited List, classified under peptide hormones and related substances. Clinical use by non-athletes is unaffected by WADA classification. Competitive athletes should not use sermorelin and should verify current prohibited list status with their sport's governing body before any GHS protocol.

How YourHealthRx approaches it

Starting with the compound with the longest safety history.

Clinician-Led GHS Protocol Design — Sermorelin as a First Step

For patients new to GH secretagogue therapy, sermorelin's established safety track record and conservative structural profile make it a natural starting point for clinician consideration. YourHealthRx connects patients with licensed clinical partners nationwide — available across all 50 states and DC through HIPAA-compliant telehealth. Partner clinicians conduct full clinical intake including medical history, cancer risk review, hormone panel baseline (IGF-1, fasting glucose, HbA1c), and individualized protocol design before any GHS compound is prescribed.

Sermorelin is dispensed through licensed 503A compounding pharmacies when clinically appropriate and when current compounding compliance is confirmed. Ongoing IGF-1 monitoring and clinical check-ins are integrated into every protocol. Clinicians may recommend sermorelin alone, sermorelin combined with ipamorelin, or a CJC-1295-based combination based on individual patient history, preferences, and response to initial therapy.

FAQ

Common questions about sermorelin.

Was sermorelin ever FDA-approved?

Yes — as Geref (Serono Laboratories) for pediatric growth hormone deficiency diagnosis and treatment. The approval was voluntarily withdrawn by the manufacturer for commercial reasons, not due to a safety action. This prior approval provides a meaningful clinical safety record that distinguishes sermorelin from compounds with no prior FDA clinical development pathway.

How is sermorelin different from CJC-1295?

Both are GHRH analogs, but sermorelin is the most structurally native (GHRH 1-29 with minimal modification) and has a shorter half-life (~10–12 minutes) compared to CJC-1295 without DAC (~30 minutes). The shorter half-life means sermorelin requires more precise bedtime timing to align with the natural nocturnal GH pulse. CJC-1295's additional amino acid substitutions provide greater enzymatic stability and a wider dosing window.

Why is bedtime the standard dosing time?

The largest endogenous GH pulse occurs during slow-wave sleep, approximately 60–90 minutes after sleep onset. Bedtime sermorelin administration aligns GHRH receptor stimulation with this natural pulsatile rhythm — maximizing physiologic relevance and potentially supporting sleep quality as a downstream effect. The short half-life makes this timing alignment particularly important for sermorelin compared to longer-acting analogs.

Is sermorelin available through compounding pharmacies?

Compounded sermorelin has a longer history than newer GHRH analogs due to its prior FDA approval status. It appears on various state pharmacy board compound lists. However, it is not on the federal 503A bulk drug substances list as of mid-2026, so compounding availability and legal status should be confirmed with a licensed compounding pharmacy and your clinician at time of consultation.

Can sermorelin be combined with ipamorelin?

Yes — sermorelin is sometimes combined with ipamorelin to achieve synergistic dual-pathway GH stimulation: sermorelin activates GHRH receptors while ipamorelin activates GHS-R1a. The two compounds are typically co-administered in the same bedtime injection. Whether monotherapy sermorelin or a combination approach is appropriate depends on individual patient assessment by your clinician.

What side effects are most common?

Injection site reactions (redness, mild swelling, itching) are the most frequently reported, along with GH-class effects: water retention, mild joint discomfort, and transient tingling. Headache has been reported, particularly in early treatment. Unlike ipamorelin, sermorelin does not activate the ghrelin receptor, so the appetite stimulation associated with ghrelin mimetics is not expected with sermorelin monotherapy.

Do I need IGF-1 monitoring on sermorelin?

Yes. Baseline IGF-1 before starting therapy, follow-up at 4–8 weeks, and periodic monitoring during ongoing treatment are standard practice. Monitoring confirms pharmacological response, guides dose titration, and ensures IGF-1 remains within a physiologically appropriate range for your age. This is standard for all GHS protocols regardless of compound.

Informational only. Content on this page is for informational purposes and does not constitute medical advice. Sermorelin has no current FDA approval for any adult indication. Compounding availability depends on current 503A regulatory status — confirm with your clinician at time of consultation. All prescriptions are issued at the sole discretion of the prescribing clinician. Not all compounds are available in all states. Last reviewed: May 2026.

Sources

References cited on this page.

Primary References

  • Sinha et al. (2020). GH secretagogues in hypogonadal males. Transl Androl Urol. DOI: 10.21037/tau.2019.11.30
  • Falutz et al. (2010). Tesamorelin Phase 3 pooled analysis (GHRH class context). J Clin Endocrinol Metab. PMID: 20554713
  • Ionescu & Frohman (2006). CJC-1295 pulsatile GH (GHRH analog comparison). J Clin Endocrinol Metab. PMID: 17018654
  • FDA NDA 20-503 — Geref (sermorelin acetate), Serono Laboratories [reference for prior approval history]

Related

Continue exploring.

CJC-1295 / Ipamorelin

The next-generation GHRH analog combination. CJC-1295's improved stability and pairing with ipamorelin's selective GHRP action makes it the most widely prescribed GHS combination in clinical telehealth settings today.

Read the CJC-1295/Ipamorelin Page

Tesamorelin

The only FDA-approved GHRH analog — and the compound with the strongest human clinical trial evidence in the GHS class. Understanding tesamorelin's Phase 3 data provides the best available context for the GHRH analog mechanism.

Read the Tesamorelin Page

Start a Clinical Evaluation

A licensed clinician can evaluate your baseline IGF-1, health history, and clinical goals to determine whether sermorelin or another GHS protocol may be appropriate for your situation. Nationwide availability — all 50 states and DC.

Start Your Intake

The GHRH analog with the longest safety track record.

A licensed clinician evaluates your baseline IGF-1 and health history before designing any GH secretagogue protocol.

Sermorelin's prior FDA approval history provides a safety foundation that newer compounds lack. Our partner clinicians operate across all 50 states and DC, with full HIPAA-compliant telehealth intake and ongoing IGF-1 monitoring built into every protocol.

Start Your Intake Back to GH Secretagogues